Extended Data Fig. 3: ORR by molecular subtypes and mutational status.

a, ORR per transcriptomically defined clustering pattern identified in the IMmotion151 phase 3 study⁸ (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). b, ORR by mutational status in the pembrolizumab plus axitinib arm (n = 347). c, ORR by mutational status in the sunitinib arm (n = 351). In panel a, “Other” includes samples that could not be assigned to angiogenic/stromal, angiogenic, immune/proliferative, proliferative, or stromal/proliferative subtype. In panels a-c, bars represent ORR, derived by dividing the number of participants with a complete or partial response by the total number of patients in that subgroup, multiplied by 100. Error bars indicate 95% confidence intervals. P values shown in panels b and c are multiplicity-adjusted (one-sided for pembrolizumab plus axitinib and two-sided for sunitinib) and were derived using logistic regression model, with adjustment for IMDC risk category. Significance was prespecified at α = 0.10. BAP1, BRCA1-associated protein 1 gene; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NS, not significant; ORR, objective response rate; PBRM1, polybromo-1 gene; SETD2, SET domain containing 2, histone lysine methyltransferase gene; VHL, von Lindau-Hippel tumor suppressor gene.